Other research analysts also recently issued research reports about the stock. SunTrust Banks increased their price objective on shares of Syneos Health to $68.00 and gave the company a buy rating in a report on Wednesday, August 7th. KeyCorp upped their target price on shares of Syneos Health from $63.00 to $65.00 and gave the company an overweight rating in a research report on Tuesday, September 3rd. Credit Suisse Group upped their target price on shares of Syneos Health from $56.00 to $58.00 and gave the company an outperform rating in a research report on Friday, August 23rd. Zacks Investment Research cut shares of Syneos Health from a buy rating to a hold rating and set a $55.00 target price on the stock. in a research report on Tuesday, September 10th. Finally, Jefferies Financial Group upped their target price on shares of Syneos Health from $62.00 to $65.00 and gave the company a buy rating in a research report on Monday, September 23rd. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $59.50.
Shares of NASDAQ SYNH traded down $0.04 during trading on Wednesday, reaching $48.00. The company had a trading volume of 298,800 shares, compared to its average volume of 574,450. The stock has a market cap of $5.09 billion, a P/E ratio of 18.32, a PEG ratio of 1.67 and a beta of 1.49. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 1.02. The company’s fifty day moving average price is $52.95 and its 200-day moving average price is $49.52. Syneos Health has a 12 month low of $36.26 and a 12 month high of $56.34.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Syneos Health by 2.1% in the second quarter. BlackRock Inc. now owns 8,533,950 shares of the company’s stock valued at $435,999,000 after acquiring an additional 172,529 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Syneos Health by 5.7% during the second quarter. Vanguard Group Inc. now owns 7,646,454 shares of the company’s stock worth $390,657,000 after purchasing an additional 415,522 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Syneos Health by 13.2% during the second quarter. JPMorgan Chase & Co. now owns 1,495,906 shares of the company’s stock worth $74,242,000 after purchasing an additional 174,481 shares during the last quarter. Boston Partners increased its holdings in Syneos Health by 41.1% in the second quarter. Boston Partners now owns 1,462,312 shares of the company’s stock valued at $74,595,000 after buying an additional 426,193 shares in the last quarter. Finally, GW&K Investment Management LLC increased its holdings in Syneos Health by 23.4% in the third quarter. GW&K Investment Management LLC now owns 1,125,797 shares of the company’s stock valued at $59,903,000 after buying an additional 213,112 shares in the last quarter.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: Purposes and Functions of the Federal Reserve
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.